Angitia Biopharmaceuticals closed a $130 million Series D to progress three biologics targeting musculoskeletal diseases into mid‑stage development. The round positions the US‑China company to press forward after mixed clinical precedents in the space and to fund trials that could validate bone‑building and cartilage‑repair mechanisms. The financing reflects investor interest in specialty biologics and therapies addressing large, underserved musculoskeletal markets. Angitia’s capital raise will also influence partnership and M&A calculations among larger orthopedics and rare disease players.